Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Emilia Quattrocchi"'
Autor:
Kathleen Weisel, Scott Berger, Katie Thorn, Peter C. Taylor, Charles Peterfy, Hilary Siddall, Debra Tompson, Susanne Wang, Emilia Quattrocchi, Susan W. Burriss, Jochen Walter, Paul Peter Tak
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experi
Externí odkaz:
https://doaj.org/article/3315ea0dbc054e6abb7df36ef9b3b2ae
Autor:
Valentin Hamy, Luis Garcia-Gancedo, Andrew Pollard, Anniek Myatt, Jingshu Liu, Andrew Howland, Philip Beineke, Emilia Quattrocchi, Rachel Williams, Michelle Crouthamel
Publikováno v:
Digital Biomarkers, Vol 4, Iss 1, Pp 26-44 (2020)
Background: Digital biomarkers that measure physical activity and mobility are of great interest in the assessment of chronic diseases such as rheumatoid arthritis, as it provides insights on patients’ quality of life that can be reliably compared
Externí odkaz:
https://doaj.org/article/c96c57ffb8684e57908ea9c95299e1f9
Autor:
Emilia Quattrocchi, Mikkel Østergaard, Peter C Taylor, Ronald F van Vollenhoven, Myron Chu, Stephen Mallett, Hayley Perry, Regina Kurrasch
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157961 (2016)
OBJECTIVES:To investigate the safety of ofatumumab retreatment in rheumatoid arthritis. METHODS:Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) recei
Externí odkaz:
https://doaj.org/article/40848c24a94e463d857780b7fec3fe33
Autor:
Antonio Venuti, Emilia Quattrocchi, Luciana Rigoli, Giovanni Branca, Anna Bonanno, Rosario A. Caruso, Giuseppe Finocchiaro, Francesco Fedele
Publikováno v:
Rare Tumors, Vol 5, Iss 2, Pp e18-e18 (2013)
Mitochondrion-rich adenocarcinomas represent a rare variant of gastric adenocarcinomas composed predominantly of columnar adenocarcinoma cells with eosinophilic cytoplasm, a strong supranuclear immunoreactivity for antimitochondrial antibody, and a m
Externí odkaz:
https://doaj.org/article/2a488e560a64423b83ef2786f06e1f46
Autor:
Rachel E. Williams, Andrew Howland, Andrew Pollard, Emilia Quattrocchi, Philip Beineke, Anniek Myatt, Luis Garcia-Gancedo, Valentin Hamy, Michelle Crouthamel, Jingshu Liu
Publikováno v:
Digital Biomarkers, Vol 4, Iss 1, Pp 26-44 (2020)
Digit Biomark
Digit Biomark
Background: Digital biomarkers that measure physical activity and mobility are of great interest in the assessment of chronic diseases such as rheumatoid arthritis, as it provides insights on patients’ quality of life that can be reliably compared
Autor:
Jochen Walter, Emilia Quattrocchi, Hilary Siddall, Susan W Burriss, Peter C. Taylor, Kathleen M. Weisel, Katie Thorn, Paul P. Tak, Susanne Wang, Charles Peterfy, Debra J. Tompson, Scott B. Berger
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Funder: GlaxoSmithKline; doi: http://dx.doi.org/10.13039/100004330
BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomiz
BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94165bb4d7b7f80229ba1ddec0ff6de0
https://ora.ox.ac.uk/objects/uuid:70da4597-e9b3-458a-b3ec-9aee56447252
https://ora.ox.ac.uk/objects/uuid:70da4597-e9b3-458a-b3ec-9aee56447252
Autor:
Jeffery K. Allen, Martin M. Crane, Maneesh Juneja, David J. Chang, Myron Chu, Regina Kurrasch, Stephanie Manson, Emilia Quattrocchi
Publikováno v:
Arthritis Care & Research. 67:1646-1655
Objective To investigate the epidemiology and treatment of rheumatoid arthritis (RA) in a population broadly representative of employed adults in the US, using a retrospective cohort design. Methods Incident and prevalent RA cohorts were defined from
Autor:
Michelle Crouthamel, Emilia Quattrocchi, Sarah Watts, Sherry Wang, Pamela Berry, Luis Garcia-Gancedo, Valentin Hamy, Rachel E Williams
BACKGROUND Using smartphones to enroll, obtain consent, and gather self-reported data from patients has the potential to enhance our understanding of disease burden and quantify physiological impact in the real world. It may also be possible to harne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed0cea9f1f8fd28c275a74684958a650
https://doi.org/10.2196/preprints.9656
https://doi.org/10.2196/preprints.9656
Autor:
Peter C. Taylor, Jørgen Petersen, Stephen Mallett, Emilia Quattrocchi, David J. Chang, Regina Kurrasch
Publikováno v:
Annals of the Rheumatic Diseases
OBJECTIVES: To evaluate the efficacy and safety of intravenous ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, active rheumatoid arthritis (RA) patients despite methotrexate treatment. METHODS: In this double-blind, plac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f674f55f4b70f96ca655bdc001c0148
https://ora.ox.ac.uk/objects/uuid:ba440a1a-4d8c-4198-8db4-01c182c98a37
https://ora.ox.ac.uk/objects/uuid:ba440a1a-4d8c-4198-8db4-01c182c98a37
Autor:
Mikkel Østergaard, Regina Kurrasch, Emilia Quattrocchi, Myron Chu, Hayley Perry, Stephen Mallett, Peter C. Taylor, Ronald F van Vollenhoven
Publikováno v:
Quattrocchi, E, Østergaard, M, Taylor, P C, van Vollenhoven, R F, Chu, M, Mallett, S, Perry, H & Kurrasch, R 2016, ' Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis : Results from Three Clinical Trials ', PLoS ONE, vol. 11, no. 6, pp. e0157961 . https://doi.org/10.1371/journal.pone.0157961
PLoS ONE
PLoS ONE, 11(6). Public Library of Science
PLoS ONE, Vol 11, Iss 6, p e0157961 (2016)
Quattrocchi, E, Ostergaard, M, Taylor, P C, van Vollenhoven, R F, Chu, M, Mallett, S, Perry, H & Kurrasch, R 2016, ' Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis : Results from Three Clinical Trials ', PLOS ONE, vol. 11, no. 6, e0157961 . https://doi.org/10.1371/journal.pone.0157961
PLoS ONE
PLoS ONE, 11(6). Public Library of Science
PLoS ONE, Vol 11, Iss 6, p e0157961 (2016)
Quattrocchi, E, Ostergaard, M, Taylor, P C, van Vollenhoven, R F, Chu, M, Mallett, S, Perry, H & Kurrasch, R 2016, ' Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis : Results from Three Clinical Trials ', PLOS ONE, vol. 11, no. 6, e0157961 . https://doi.org/10.1371/journal.pone.0157961
OBJECTIVES: To investigate the safety of ofatumumab retreatment in rheumatoid arthritis.METHODS: Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::785ff028d151621cc6bdf62f66076a72
https://research.vumc.nl/en/publications/9b75d253-3158-476d-9d03-4fcb6ad2823e
https://research.vumc.nl/en/publications/9b75d253-3158-476d-9d03-4fcb6ad2823e